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Abstract
Background: Extensive evidence from observational studies suggests a role for genital herpes in the HIV epidemic. A
number of herpes vaccines are under development and several trials of the efficacy of HSV-2 treatment with acyclovir in
reducing HIV acquisition, transmission, and disease progression have just reported their results or will report their results in
the next year. The potential impact of these interventions requires a quantitative assessment of the magnitude of the
synergy between HIV and HSV-2 at the population level.
Methods and Findings: A deterministic compartmental model of HIV and HSV-2 dynamics and interactions was
constructed. The nature of the epidemiologic synergy was explored qualitatively and quantitatively and compared to other
sexually transmitted infections (STIs). The results suggest a more substantial role for HSV-2 in fueling HIV spread in sub-
Saharan Africa than other STIs. We estimate that in settings of high HSV-2 prevalence, such as Kisumu, Kenya, more than a
quarter of incident HIV infections may have been attributed directly to HSV-2. HSV-2 has also contributed considerably to
the onward transmission of HIV by increasing the pool of HIV positive persons in the population and may explain one-third
of the differential HIV prevalence among the cities of the Four City study. Conversely, we estimate that HIV had only a small
net impact on HSV-2 prevalence.
Conclusions: HSV-2 role as a biological cofactor in HIV acquisition and transmission may have contributed substantially to
HIV particularly by facilitating HIV spread among the low-risk population with stable long-term sexual partnerships. This
finding suggests that prevention of HSV-2 infection through a prophylactic vaccine may be an effective intervention both in
nascent epidemics with high HIV incidence in the high risk groups, and in established epidemics where a large portion of
HIV transmission occurs in stable partnerships.
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Introduction
Human immunodeficiency virus (HIV) infection continues to be
among the leading causes of global morbidity and mortality,
especially in Africa. An estimated 40 million people are HIV
infected with an annual mortality of three million [1]. The rapid
spread of HIV as a sexually transmitted infection is exceeded by
that of herpes simplex virus type 2 (HSV-2) [2,3,4]. The
trajectories of HIV and HSV-2 incidence and prevalence contrast
with the decline of bacterial sexually transmitted infections (STIs)
in sub-Saharan Africa [5,6,7,8,9]. Indeed, the prevalence of HSV-
2 has already reached high seroprevalence, of up to 90% in HIV-
positive persons, and HSV-2 is now the leading cause of genital
ulcer disease (GUD) in both developing and developed countries
[2,4,10,11].
The chronic nature of HSV-2 infection with frequent and
mostly unrecognized reactivations [12,13], and its relatively large
transmission probability per coital act [14,15], leads HSV-2 to
having a different epidemiology among STIs. As opposed to
bacterial infections such as gonorrhoea or syphilis, the threshold
for sustainable transmission of HSV-2 at the population level is
comparatively very low (Table 1). While bacterial STIs tend to be
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sustainable in the general population, and therefore its prevalence
can reach very high levels such as those observed in diverse regions
around the globe [4,17]. Consequently, the epidemiological
overlap between HSV-2 and HIV is substantially larger than that
of any other bacterial STI with HIV. This is supported by the
epidemiological data that indicates that globally HIV-1 and HSV-
2 have overlapping prevalence patterns [17,18,19,20,21].
The epidemiological overlap between the two viruses, and the
nature of HSV-2 infection as a leading cause of clinical and sub-
clinical genital ulceration and mucosal disruption, have focused a
role for HSV-2 in the elevation of the HIV pandemic since the late
eighties [22]. Two systematic reviews of 18 longitudinal studies
showed that HSV-2 seropositivity has a relative risk of 2 or higher
for HIV acquisition, after controlling for sexual behavior [23,24].
These epidemiologic observations have been corroborated by
evidence of biological plausibility. CD4+ lymphocytes, HIV target
cells, have been detected in herpetic lesions [25,26], which could
increase HIV susceptibility during sexual exposure.
Further, the evidence that HSV-2 increases HIV transcription in
vitro [27,28,29,30,31] potentially explains the high levels of HIV-1
RNA seen in herpetic lesions [32] and in plasma in dually infected
patients [33,34,35], and supports higher HIV infectivity in dually
infected subjects [36]. This has been corroborated by epidemio-
logic studies that suggested a relative risk of two to five fold of
transmitting HIV from persons co-infected with HSV-2 compared
to persons who are HSV-2 seronegative [37,38]. In addition, HIV
infection has been shown to substantially increase mucosal HSV-2
shedding [39,40,41,42,43,44,45]. These observations led to several
proof-of-concept placebo-controlled trials to assess the effect of
HSV-2 suppression on HIV infectiousness. The trials demonstrat-
ed significant reductions of up to 0.5 log10 in plasma viral load and
up to 0.3 log10 in genital HIV load among HIV-HSV-2 coinfected
persons during HSV-2 suppression [46,47,48,49,50,51].
This body of knowledge suggests an epidemiologic synergy
between the two diseases at the population level [52]. Some
features of this interplay have been explored using mathematical
models [5,6,53,54]. Furthermore, population ecological studies
have examined this conjecture. Most notably the cross-sectional
population-based Four City study examined the differential spread
of HIV in four sub-Saharan Africa cities in the late nineties [11]. It
found that differences in reported sexual behavior patterns could
not explain the disparity in HIV spread [55,56,57], and concluded
that biological mechanisms, primarily male circumcision and
HSV-2 infection, may explain the stark differences in HIV
prevalence across the four cities [58].
The epidemiologic synergy of the two infections may be a factor
in explaining the lack of effect of two large STI intervention trials
in reducing HIV incidence [59,60,61]. The interventions involved
primarily syndromic management or mass treatment of bacterial
STIs, and did not incorporate HSV-2 treatment even though
HSV-2 was far more prevalent than all other bacterial STIs
combined [62]. For example in Rakai, genital herpes was
identified to be the cause of almost half of all genital ulcers in
the mid nineties during the STI treatment trial [63].
Thus, HSV-2 could have a major role in fueling HIV spread
and, if HSV-2 could either be prevented or suppressed, potentially
significant numbers of HIV infections could be averted. At present
no vaccine to prevent HSV-2 acquisition or reactivation has been
developed while the antivirals acyclovir, valaciclovir and famci-
clovir have been shown to be safe and effective in reducing HSV-2
shedding frequency and duration of genital ulcer disease
[64,65,66]. Several trials have been conducted or currently under
progress to measure the effect of acyclovir suppressive therapy in
reducing HIV acquisition among HIV seronegatives, reducing
HIV transmission from HIV and HSV-2 dually infected persons,
and reducing HIV disease progression [67]. Two recent trials
reported no efficacy of HSV-2 suppressive therapy on reducing
HIV acquisition [68,69]; an unexpected outcome considering the
extensive and consistent evidencefor epidemiologic synergybetween
the two infections. The mechanisms behind this failure are as yet
unclear and may involve compliance to daily medication as well as
the inability of the medication or regimen to suppress all types of
subclinical reactivation. For example, the immune response to the
HSV-2 virus in the genital tract may have not been reduced with
therapydespite the reduction inulcerations.Immune responseto the
HSV-2 virus in the genital tract, as indicated by increased density of
CCR5+CD4cellsandimmaturedendriticcells[70]andlocalization
ofHSV-specificCD8cellsatgenitalHSV-2reactions[71],mayhave
not been reduced with therapy despite the partial reduction in
Table 1. Threshold for sustainable transmission and transmission probability per partnership for key sexually transmitted
infections
*.
Agent
Duration of
infectiousness in
years Transmission probability per partnership
Effective mean rate of new
sexual partner acquisition per
year for sustainable
transmission
One-year
partnership
Ten-year
partnership
Twenty-year
partnership
Neisseria gonorrhoeae (gonorrhea) [16,93] 0.5 0.50 0.50 0.50 4
Chlamydia trachomatis (chlamydia) [16,119] 1.25 0.20 0.20 0.20 4
Treponema pallidum (syphilis) [16,94] 0.5 0.30 0.30 0.30 7
Haemophilus ducreyi (chancroid) [16,120] 0.08 0.80 0.80 0.80 15
Herpes simplex sirus type 2 (HSV-2) chronic reactivations
for lifetime
0.20 0.89 0.99 0.4
{{
Human immunodeficiency virus type 1 (HIV-1) 10 0.16 0.83 0.83 1.4
1
*Appendix S1 includes the formulae used for our calculations for HIV and HSV-2. The values for the rest of the STIs are extracted from the cited references.
{Note that although HSV-2 transmission probability per partnership is not much larger than that of HIV, HSV-2 infectious spread is much more invasive since the
absence of disease mortality allows HSV-2 infected persons to spread the infection in more sexual partnerships over their lifetime.
{The minimum effective new sexual partner acquisition rate is calculated assuming mean representative partnership duration of six months (Protocol S2).
doi:10.1371/journal.pone.0002230.t001
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HSV-2 DNA in ulcers [68]).
Furthermore, the relative effect of HSV-2 on HIV acquisition
versus HIV transmission is not yet known and it is possible that
most of the effect could be on enhancing HIV infectiousness rather
than acquisition. The Partners in Prevention trial, in which the
HIV/HSV-2 co-infected partner is randomized to HSV-2
suppression or placebo, will shed light on the impact on
infectiousness [67]. Already several proof-of-concept placebo-
controlled trials to assess the effect of HSV-2 suppression on HIV
viral load, the principal predictor of HIV transmission probability
per coital act [36], have demonstrated reductions of up to 0.5 log10
in plasma viral load and up to 0.3 log10 in genital HIV load among
HIV-HSV-2 coinfected persons [46,47,48,49,50,51]. Besides
reducing HIV infectiousness, these reductions in viral load may
imply slower disease progression to AIDS and death [67].
Freeman et al. have recently presented an analysis of the role of
HSV-2 in HIV infectious spread based on the role of HSV-2 in
causing GUD [72]. However, numerous studies in the last few
years have shown that at least 75%, of all mucosal ulcerations due
to HSV-2 in males and females are not clinically apparent
[73,74,75]. ‘‘Subclinical’’ ulcerations that are not in noticeable
anatomic areas, such as in the cervix or rectum, or are too small to
be apparent on the vulva or penis, are much more common than
clinical manifestations of herpes reactivations. In a recent study in
which samples for mucosal detection of HSV-2 were taken 4 times
daily, over 50% of HSV-2 ulcerations lasted less than 12 hours
and only 15% of all episodes of HSV-2 shedding were associated
with noticeable lesions [76]. Notably, no differences in HSV-2
shedding and reactivation have been observed among HSV-2
seropositive persons who do not report a history of GUD compared
tothosewithahistoryofGUD[12].Naturalhistorystudieshavealso
shownsmallalterationsinreactivationpatternsofindividualsover10
years, and drug treatment trials involving persons treated for 6–10
years have shown the virus persists [77]. This paper provides our
analysis of the interaction between HIV and HSV-2 based on the
biological observation that subclinical ulcerations and reactivations
play the leading role, as opposed to GUD, in driving the epide-
miological synergy between HIV and HSV-2 seen in observational
studies [23,24]. Our approach to this analysis is further supported by
the numerous clinical and laboratory based studies that have shown
the upregulation of HIV during subclinical HSV-2 infection
[27,28,29,30,31,32,33,34,35], as well as the recent evidence that
subclinical HSV-2 infection is associated with the detection of higher
copies of mucosal HIV RNA in the trials that demonstrated
significant reductions in HIV plasma viral load and genital HIV
shedding during HSV-2 suppression irrespective of clinical symp-
toms [46,47,48,49].
To better assess the impact of HSV-2 on HIV epidemiology, we
estimate the magnitude of the population-level epidemiologic
synergy between the two viruses implied by the interaction
demonstrated at the individual level. We address this question by
synthesizing the biological and epidemiological observations into a
mathematical model from which quantitative predictions can
establish the magnitude of the synergy. Although the biological
interaction between HIV and HSV-2 has been a subject of
investigation by numerous studies, the parameters of some
components of the interaction are not yet satisfactorily determined.
The fact that both viruses share the same route of transmission,
throughsexualcontact,makesitchallengingtodisentanglebiological
from behavioral mechanisms as confounding by sexual behavior
[52,78,79,80] may be one explanation for the substantial variability
in study outcomes [23,24]. The diversity of study designs and the
heterogeneity in individual HSV-2 reactivation rates [12] further
complicate estimations of some parameters [24]. With these
considerations in mind, we investigate the synergy under two sets
of assumptions for the interaction parameters. We also explore the
size of the synergy in different settings and examine the differences
between the role of HSV-2 in enhancing HIV acquisition versus its
role in enhancing HIV infectivity.
Methods
Model structure
A deterministic compartmental model was constructed to
describe HIV and HSV-2 transmission and acquisition dynamics
and their interaction. The model consists of thirty-two coupled
nonlinear ordinary differential equations that stratify the popula-
tion into compartments according to HIV infection status and
stage, HSV-2 infection status and stage, and the sexual risk activity
class. HIV progression is divided into three stages of acute,
chronic, and advanced, while HSV-2 infection is depicted by the
three stages of primary infection, latent infection, and reactivation.
Dual infection is characterized by nine stages according to each of
HIV and HSV-2 stages. The population is divided into two sexual
risk behavior classes of low-risk population (‘‘general population’’)
and high risk group (‘‘core group’’). The mixing between the
sexual activity classes has assortative (choosing partners only from
within their risk group) and proportionate (choosing partners with
no preferential bias based on the kind of risk group) components.
Our model calculates the size of the synergy between the two
infections where the synergy is defined as the combined effect on
HIV epidemiology of the presence of enhanced risk of HIV
acquisition in HSV-2 seropositive subjects, enhanced HIV
infectivity in dually infected persons, and enhanced HSV-2
shedding in dually infected persons. The structure of the model
along with all parameter definitions are delineated in Protocol S1.
Key assumptions and parameter values
The parameter values of the model are chosen according to the
best available empirical evidence of the biology, epidemiology, and
interaction of the two infections. In particular, this is the first
modeling assessment where the recently established detailed
empirical data about the pattern of HSV-2 reactivation in its clinical
and subclinical form has played a central role in the model. Table 2
lists the key assumptions of the model. The per-exposure cofactor
provides the multiplicative impact of a given risk on HIV
transmission probability per coital act. The susceptibility enhance-
ment per-exposure cofactor of PECAcq=4 and PECAcq=9 during
HSV-2 primary infection and reactivations (i.e. HSV-2 shedding),
irrespective of whether HSV-2 infection is manifested clinically or
subclinically, are derived in Protocol S2 from the overall risk ratios
(RR) of HIV acquisition in HSV-2 seropositive persons as estimated
in two meta-analyses at RR values of 2.1 [24] and 2.9 [23],
respectively. We assume an infectivity enhancement per-exposure
cofactor of PECTrans=3 in dually infected persons during HSV-2
primary infection and reactivations irrespective of clinical symptoms
as a representative value of the combined effect of HSV-2 induced
increase in HIV transcription [27,28,29,30,31], the measured
heightened HIV plasma viral load in dually infected patients
[33,34,35,46,47,48] (and its implication in terms of HIV infectious-
ness [36]), and the presence of HIV-1 RNA in herpetic lesions [32].
Protocol S2 includes more discussion of the rationale for this value.
We hypothesize that the enhanced susceptibility and infectivity do
not occur in absence of HSV-2 shedding in view of the lack of a
plausible biological mechanism during HSV-2 latency.
Although there are substantial variations in the pattern (and
frequency) of HSV-2 reactivations [13,76], the critical parameter
Genital Herpes/HIV Epidemic
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Parameter Value References
HIV transmission probability per coital act per stage of
HIV infection:
Acute stage 0.0107 [88,115] (Protocol S2)
Chronic stage 0.0008 [88,115] (Protocol S2)
Advanced stage 0.0042 [88,115] (Protocol S2)
Duration of each of HIV stages:
Acute stage 2.5 months [115]
Chronic stage 7.59 years [83,84] (Protocol S2)
Advanced stage 2.0 years [115]
Susceptibility enhancement to HIV acquisition per-
exposure cofactor during HSV-2 shedding (PECAcq)
4.0 derived based on meta-analysis in [24] (Protocol S2)
Figures 1, 3 (for the PECAcq=4 calculations), 4A, 4C, and 5
9.0 derived based on meta-analysis in [23] (Protocol S2)
Figures 2, 3 (for the PECAcq=9 calculations), 4B, and 4D
HIV infectivity enhancement per-exposure cofactor
in dually infected subjects during HSV-2 shedding
(PECTrans)
3.0 representative assumption based on [33,34,35,46,47,48]
(Protocol S2)
HSV-2 shedding frequency among:
HIV susceptible persons 14% of the time [76]
Acute and chronic HIV persons 20% of the time [17,43,76] (Protocol S2)
Advanced HIV persons 31% of the time [17,43,76] (Protocol S2)
HSV-2 transmission probability per coital act model fit informed by [14,15] (Protocol S2)
0.0116 Figures 1, 3 (for Kisumu at PECAcq=4), 4A, and 4C
0.0144 Figures 2, 3 (for Kisumu at PECAcq=9), 4B, and 4D
0.00343 (PECAcq=4) and 0.00407 (PECAcq=9) Cotonou calculation model fit in Figure 3
0.00632 (PECAcq=4) and 0.00757 (PECAcq=9) Yaounde ´ calculation model fit in Figure 3
0.0084 (PECAcq=4) and 0.01021 (PECAcq=9) Ndola calculation model fit in Figure 3
Duration of the HSV-2 cycle of latency and reactivation 4 per year [13]
Duration of HSV-2 stages:
Primary infection 20.0 days representative assumption informed by [13] (Protocol
S2)
Latency between HSV-2 reactivations for HIV
seronegative persons
78.5 days derived (Protocol S2)
Latency between HSV-2 reactivations for HIV
seropositive persons in acute or chronic stages
73.0 days derived (Protocol S2)
Latency between HSV-2 reactivations for HIV
seropositive persons in advanced stage
63.0 days derived (Protocol S2)
Shedding during reactivation for HIV seronegative
persons
12.8 days derived (Protocol S2)
Shedding during reactivation for HIV seropositive
persons in acute or chronic stages
18.3 days derived (Protocol S2)
Shedding during reactivation for HIV seropositive
persons in advanced stage
28.3 days derived (Protocol S2)
Frequency of coital acts:
Acute stage 10.6 per month [115]
Chronic stage 11.0 per month [115]
Advanced stage 7.1 per month [115]
Fraction of the high risk group in the population 11.3% derived based on behavioral measures in [55,56,57]
(Protocol S2)
Number of sexually active people in the population at
the start of the simulation
200,000 representative assumption based on [57,121,122,123]
(Protocol S2)
Number of people in the low risk group at the start of
the simulation
177,400 derived (Protocol S2)
Number of people in the high risk group at the start
of the simulation
22,600 derived (Protocol S2)
Genital Herpes/HIV Epidemic
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is that of short but frequent reactivations or long but less frequent
ones since by assumption the synergy acts whenever there is
shedding and irrespective of the pattern of shedding. The model
predictions were invariable by keeping the shedding frequency
fixed, but varying the pattern of shedding.
Prospective partner and time to HSV-2 studies indicate a value
for HSV-2 transmission probability per coital in the range of
0.0005 to 0.022 [14,15]. We derived two rough estimates for this
probability using the cohort data of Corey et al. [64] and the
EXPLORE behavioral intervention study of men who have sex
with men [81]. The calculations suggest a value of 0.01 which is in
the middle of the range indicated by prospective partner and time
to HSV-2 studies (Protocol S2). In absence of precise estimates, we
use the HSV-2 transmission probability per coital act as one of the
model fitting parameters, but constrain its value to be in the range
suggested by the empirical data. The model fitting suggests a value
in the neighborhood of 0.01 which is consistent with the derived
rough estimates.
Due to insufficient evidence, we conservatively assume that dual
infection does not increase HSV-2 transmission probability per
coital act or HIV disease progression [82,83,84,85], although
HSV-2 seropositivity was reported to increase systemic HIV virus
levels significantly during acute and chronic HIV infection [86].
We further assume that HIV seropositivity does not biologically
enhance the susceptibility to HSV-2 infection. The behavioral
parameters in the model are informed by the measurements of the
Four City study [55,56,57]. Their exact values are obtained
through the model fits which yield reasonable estimates for these
parameters (Protocol S2 and Table 2). More details regarding the
model parameters and their related analyses can be found in
Protocol S2.
Measures of epidemiologic synergy
We estimate the size of the epidemiologic synergy first using the
population attributable fraction of HIV due to HSV-2 infection
defined as
PAF t ðÞ ~
Actual incidence of HIV directly due to HSV   2 at time t
Total actual incidence of HIV at time t
This definition expresses the direct role of HSV-2 in HIV incident
cases at each time point t in the epidemic [87]. We define three
PAF measures. First, PAFSus(t) which measures the percentage of all
incident HIV infections at time t that are directly caused by the
enhanced susceptibility of HSV-2 seropositive persons to HIV
acquisition [24]. Second, PAFInf(t) which measures the percentage
of all incident HIV infections at time t that are directly caused by
the enhanced HIV infectivity in dually infected persons. Third,
PAFSus+Inf(t) which measures the percentage of all incident HIV
infections at time t that are directly caused by HSV-2 whether due
to enhanced susceptibility or infectivity.
The PAFSus+Inf is not simply a sum of PAFSus and PAFInf since
there are incident HIV cases that can be attributed causally to
both enhanced susceptibility and enhanced infectiousness. This
occurs if an HSV-2 seropositive subject in sexual partnership with
a dually infected person acquires HIV because HSV-2 increases
concurrently the susceptibility to HIV and the infectivity of the
HIV/HSV-2 coinfected partner. Therefore, PAFSus+Inf#PAFSus+
PAFInf since some incident cases are counted in each of PAFSus and
PAFInf, but counted only once in the PAFSus+Inf.
Accordingly, the PAF estimates the fraction of incident HIV
cases that are caused by the direct biological effects of HSV-2. But
as opposed to non-infectious diseases, any HIV infection caused by
HSV-2 can also generate onward transmission of secondary HIV
infections regardless of HSV-2 as a cofactor. Such secondary
infections are considered indirect effects of HSV-2 role in HIV
epidemiology and are not counted in the PAF measures. However,
these indirect effects affect HIV epidemiology and prevalence.
Therefore we use HIV excess prevalence [88] as an additional
measure of the synergy. HIV excess prevalence is defined as the
difference in HIV prevalence in a scenario where there is a
Table 2. cont.
Parameter Value References
The effective new sexual partner acquisition rate: representative assumptions based on model fits and
informed by [55,56,57] (Protocol S2)
Low-risk population 0.406 partners per year model fit in Figures 1, 3 (at PECAcq=4), 4A, and 4C
0.371 partners per year model fit in Figures 2, 3 (at PECAcq=9), 4B, and 4D
0.401 partners per year model fit in Figure 5
High risk group 26.000 partners per year model fit in Figures 1, 3 (at PECAcq=4), 4A, and 4C
21.000 partners per year model fit in Figures 2, 3 (at PECAcq=9), 4B, and 4D
30.000 partners per year model fit in Figure 5
Degree of assortativeness 0.2 representative assumption based on model fit and
informed by [55,56,57] (Protocol S2)
Duration of sexual partnerships:
Among the low-risk population 36 months representative assumption informed by [55,56,57]
(Protocol S2)
Among the high risk population 1 months representative assumption informed by [55,56,57]
(Protocol S2)
Between the low-risk and high risk populations 6 months representative assumption informed by [55,56,57]
(Protocol S2)
Duration of the sexual lifespan 35 years [124]
doi:10.1371/journal.pone.0002230.t002
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factual scenario where there is no biological interaction between
the two diseases. Analogously, we define HSV-2 excess prevalence
which provides a measure of the impact of HIV on HSV-2
epidemiology.
Uncertainty and sensitivity analyses of the key
parameters and basic assumptions in the model
We conducted uncertainty and sensitivity analyses of the key
parameters in the model, examined the size of the epidemiologic
synergy as a function of susceptibility and infectivity enhance-
ments, and discussed the impact of structural changes in the model
such as explicit incorporation of other sexually transmitted
infections in the model. The details of these analyses can be
found in Protocol S3.
Results
Analysis
We examine the impact of the interaction in Kisumu, Kenya, a
setting with relatively high HIV and HSV-2 prevalences, as a
representative locality to examine the epidemiologic synergy.
Kisumu is also one of the four cities in the Four City study that
assessed the differential prevalence of HIV in sub-Saharan Africa
[89]. We first examine the impact under the assumption that
PECAcq=4 (implicitly RR=2.1 [24] (Protocol S2)). Figure 1A
depicts the time course of the epidemics in terms of prevalences in
the presence of the two disease interaction and compare it to the
prevalences in a counter-factual scenario where no interaction is
assumed. Figure 1B and 1C display the PAFSus, PAFInf, PAFSus+Inf,
and HIV and HSV-2 excess prevalences.
Roughly 25% of all incident HIV infections throughout the
epidemic are attributed directly to HSV-2 (Figure 1B). Half of
these infections were caused by the enhanced susceptibility of
HSV-2 seropositives to HIV infection while the other half was
caused by the enhanced HIV infectivity in dually infected patients.
Although PECAcq=4.PECTrans=3, the effect of enhanced infec-
tivity was slightly larger as dually infected persons have more
frequent HSV-2 reactivations.
The HIV and HSV-2 excess prevalences in Figure 1C illustrate
how HSV-2 has played a major role in fuelling HIV spread
directly and indirectly particularly in the early stage of the
epidemic though HIV has limited impact on HSV-2 prevalence
throughout the HIV epidemic. This confirms earlier findings that
HSV-2 [53] and other STIs [6,7] may have accelerated the
evolution of the HIV epidemic. However, though the direct role of
HSV-2 in causing 25% of HIV infections remained rather stable
throughout the epidemic, the indirect effect in terms of secondary
HIV infections and onward HIV transmission declined steadily
with time as the number of persons susceptible to HIV diminished
due to the rising HIV prevalence.
Figure 2 displays the anticipated impact of the interaction if the
PECAcq=9 (implicitly RR=2.9 [23] (Protocol S2)). Here roughly
35% of all incident HIV infections throughout the epidemic are
attributed directly to HSV-2. Roughly two-third of these infections
were caused by the enhanced susceptibility to HIV and one-third
was caused by the enhanced HIV infectivity.
The above results indicate that at the time of the Four City
study (1997–1998), the interaction has contributed 14% in excess
HIV prevalence if PECAcq=4 (Figure 1C) and 22% if PECAcq=9
(Figure 2C). To assess the role of HSV-2 in contributing to the
differences in HIV prevalence between the cities of the Four City
study [58], we calculated HIV prevalence in 1997 using all other
biological and behavioral parameters fixed to those in Kisumu, but
imposing HSV-2 prevalence levels as those found in the four cities
of the survey [11] (Figure 3). Notably the Four City study found
sexual-risk behavior measures to be similar overall across the four
cities [55,56,57,58] suggesting that our results may be generaliz-
able to other settings that share Kisumu’s HIV and HSV-2
prevalence levels. We performed the calculations for the scenarios
of PECAcq=4 and PECAcq=9 by varying HSV-2 transmission
probability per coital act to fit HSV-2 prevalence in the four cities.
Figure 3 shows HIV prevalence as predicted by the model
compared to the prevalence as measured in the survey versus the
four HSV-2 prevalence levels. The calculations signify that HSV-2
indeed explains part of the gap in HIV prevalence between the low
and high prevalence cities. If HSV-2 prevalence in Kisumu was at
21% as in Cotonou, Benin, then HIV excess prevalence would
have been 6.1% (if PECAcq=4) or 8.4% (if PECAcq=9). These
values suggest that the epidemiologic synergy between HIV and
HSV-2 accounts for about a third of the gap in HIV prevalence
(roughly 6–9% out of 20%) in Kisumu compared to Cotonou.
This finding highlights how HSV-2, in addition to other biological
cofactors such as male circumcision [90], can fuel and maintain a
substantial differential prevalence of HIV across diverse geo-
graphic areas that have similar sexual risk behavior patterns.
Figure 4A and 4B show the incidence of HIV infections attributed
directly to HSV-2 per risk group in the Kisumu calculations of
Figure 1 and 2 respectively, and Figure 4C and 4D display the
cumulative incidence (actual number of HIV infections) per risk
group since 1980 for the same calculations. The results illustrate the
key role of HSV-2 in the dynamics of HIV transmission, irrespective
of the value of PECAcq, and its large impactin the low-risk population
with stable and long-term partnerships. Initially, HSV-2 facilitated
HIV transmission mainly in the high risk groups, but this effect was
short-livedasthehighriskpopulationwasquicklyinfectedwithHIV.
By the late 1980s, the number of incident infections attributed to
HSV-2 in the high risk population decreased substantially due to
saturation in the high-risk population, but increased among the low-
risk population peaking in the early 1990s. As opposed to the high
risk group, the epidemic phase of HIV was slow to decline and the
cumulative number of new infections attributed to HSV-2 continues
to increase. By 1994 more than 50% of the cumulative number of
HIV infections attributed directly to HSV-2 were estimated to have
occurred in the low-risk population (Figure 4C and 4D). The role of
HSV-2 in the later stages of the HIV epidemic, as opposed to
bacterial STIs, has been also reported by Orroth et al. [54] and
Freeman et al.[72]
In addition to examining the role of HSV-2 ina specific epidemic,
we examined the impact of HSV-2 in diverse settings assuming
PECAcq=4. Figure 5 displays the epidemiologic synergy measures
assuming 0–60% HSV-2 prevalence, where this range reflects the
global variability of HSV-2 prevalence among the general
population [2,3,4]. The measures are calculated at the endemic
equilibrium to disentangle interaction-strength effects from temporal
effects. As indicated in the figure, the level of HSV-2 prevalence
dictates the magnitude of the impact on HIV. When HSV-2
seropositivity is high, up to 25% of incident HIV infections are
etiologically attributed to HSV-2. The impact of enhanced
susceptibility to HIV increases moderately, but steadily, with
HSV-2 prevalence. However, the impact of HSV-2 of enhanced
HIV infectivity increases rapidly up to HSV-2 prevalence of 10%
and then increases slowly. The rapid increase in PAFInf reflects HIV
spread in the high risk group, here comprising 11% of the
population, while the slow growth represents the spread in the low
risk group following saturation in the high risk group. This result
underscores how dually infected persons in the high risk group are
essentially a group of HIV ‘‘super-spreaders’’ since the effect of their
Genital Herpes/HIV Epidemic
PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2230Figure 1. Time course of the HIV epidemic in Kisumu, Kenya. Here assuming a susceptibility enhancement per-exposure cofactor of PECAcq=4
(implyingaRR=2.1[24]).Theupperpanel(A)showsHIVandHSV-2prevalencesinthepresenceofthetwodiseaseinteractioncomparedtotheprediction
in the absence of interaction. The references for the data are discussed in Protocol S2. The middle and lower panels show the epidemiologic synergy
measures of HIV and HSV-2 interaction. The middle panel (B) displays the fraction of all incident HIV infections that are directly caused by the enhanced
susceptibility of HSV-2 seropositive persons to HIV acquisition (PAFSus), the fraction of all incident HIV infections that are directly caused by the enhanced
HIV infectivity in dually infected persons (PAFInf), and the fraction of all incident HIV infections that are directly caused by HSV-2 biology whether due to
enhanced susceptibility or enhanced infectivity (PAFSus+Inf). The lower panel (C) shows HIV and HSV-2 excess prevalences.
doi:10.1371/journal.pone.0002230.g001
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sexual networks and their partners’ high risk behavior. High risk
groups in areas where HSV-2 prevalence is low but rising should be
a primary target of HIV and HSV-2 interventions.
The impact of genital herpes on HIV epidemiology can be
analytically understood in terms of the impact of the interaction on
the HIV basic reproductive number (R0); the number of secondary
infections that an index case would generate upon entrance into an
Figure 2. Time course of the HIV epidemic in Kisumu, Kenya. As in Figure 1, but now assuming PECAcq=9 (implying RR=2.9 [23]).
doi:10.1371/journal.pone.0002230.g002
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2230infection-free population [91]. In order for an infection to spread,
R0 needs to be larger than one. If R0,1, the number of secondary
infections each index case produces is on average less than one and
the infection cannot sustain itself and dies out. If R0.1, but still
close to R0=1, the prevalence increases rapidly with each
incremental increase in R0.I fR0 is much larger than one, the
prevalence becomes insensitive to any further increases in R0 due
to susceptible depletion. Hence, the most consequential change in
the biology of an infectious pathogen is when it makes the
transition from a non-sustainable infection to a rapidly spreading
infection when it crosses the threshold at R0=1.
Since sexual risk behavior is characterized by substantial
heterogeneity, each risk group in the population has its own R0.
An STI can be sustainable and endemic in some risk groups (such as
sex workers) while being below the sustainability threshold in other
groups. Indeed, this is the case for bacterial STIs such as gonorrhea
and syphilis [16,92,93]. These infections are sustainable only if the
effective new sexual partner acquisition rate (r), is larger than an
estimated 4 (gonorrhea) [16,93] and 7 (syphilis) [16,94] partners per
year (Table 1). Though these infections can still spread in the lower
risk groups, the chain of transmission is not sustainable.
The variability in the infectious spread of STIs per risk group
leads to the concept of group of sustainable transmission (GST)
[16,92,93]. The GST for a specific STI is the population where
the infection’s chain of transmission is sustainable (R0.1). It bears
notice that the GST is sometimes labeled as the core group of
transmitters (CGT) [16,92]. We adopted a different terminology
here to avoid confusion with the concept of core group defined as
a small subgroup of the population with extremely higher risk
behavior than the rest of the population [95].
We calculated, using R0 and the equations described in Appendix
S1, the minimal value of r that is needed to sustain each of HSV-2
and HIV infections in a uniform risk population in absence of
synergy between the two infections. We found that HSV-2 is
sustainable in any population with r.0.4 partners per year, while
HIV needsatleasta r=1.4partnersperyearforsustainability.Here
and for all calculations of the threshold value of r we assumed an
average representative partnership duration of 6 months (Protocol
S2). Hence, HSV-2 has a much larger GST than HIV or any of the
bacterial STIs (Table 1), andits GST may encompassthe majorityof
the population in sub-Saharan Africa considering its observed
prevalence [2,3,4] and reported sexual behavior measures
[55,56,57,89]. Despite the larger transmission probability per coital
act of many bacterial STIs, the chronic nature of HSV-2 infection,
compared to the short infectious period of bacterial STIs, leads to
HSV-2 transmission probability per partnership growing steadily
with the duration of partnership (Table 1 and Appendix S1).
Although the HIV GST encompasses only a fraction of the
population, the biological interaction between HIV and HSV-2
changes the dynamics considerably. The HSV-2 seropositive
population with a r in the range of 1.1 to 1.4 per year if PECAcq=4
(andintherangeof0.9to1.4ifPECAcq=9),becomeseffectivelypartof
the HIV GST. These values were calculated numerically by finding
the threshold value of r at which HIV prevalence at the endemic
equilibriumbecomesnon-vanishinginauniformriskpopulation[96].
Hence,thesynergybetweenHSV-2andHIVallowedHIVtoreacha
substantiallylargerfractionofthegeneralpopulationthanwaspossible
without the biological interaction (Figure 6).
Discussion
Our findings suggest a major role for HSV-2 in fueling HIV
transmission and acquisition in Africa, where HSV-2 may account
for 25% to 35% of incident HIV infections. The contribution of
Figure 3. HSV-2 and the findings of the Four City study [58]. HIV prevalence in 1997 in the four cities as predicted by the model for the
scenarios of PECAcq=4 and PECAcq=9 compared to HIV prevalence as measured in the survey [89], versus HSV-2 prevalence in the four cities [11]. The
calculations were done using the same sexual behavior parameters as those in Kisumu. The figure estimates the magnitude of HSV-2 contribution to
the differential HIV prevalence across the four cities.
doi:10.1371/journal.pone.0002230.g003
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increasing the fraction of the population at risk of HIV acquisition
and once co-infected, results in them becoming more infectious for
HIV, and increasing the pool of HIV infected persons in the
general population.
The results of the Four City study [58] corroborate our findings.
In the two West African cities with lower HSV-2 prevalence, HIV
remained concentrated in higher risk groups whereas in the cities
with high HSV-2 prevalence, HIV transmission was observed in a
large fraction of the population. Here, HSV-2 was a trigger for the
explosive expansion of HIV. Lack of male circumcision may have
impacted HIV epidemiology similarly [90,97]. The role of HSV-2 in
the HIV epidemic is in sharp contrast to the role of bacterial STIs.
Bacterial STIs are concentrated in the high risk groups and
principally served as a co-factor for increasing HIV susceptibility
and infectiousness in the high-risk population, but their role
diminished as HIV prevalence increased in the low-risk population
[6,7,54,98,99,100]. In contrast, HSV-2 has maintained its contri-
bution to the epidemic as HIV moved to the low-risk population.
Our results indicate that genital herpes may explain as a much
as a third of the gap in HIV prevalence between the four cities of
the Four City study [11,58]. Nevertheless, HSV-2 alone cannot
explain the differential prevalence; and other factors, such as lack
of male circumcision, likely play a role. Indeed, the Four City
study [58,97], numerous observational studies [101], a modeling
study [90], and the striking magnitude of protection against HIV
infection reported in three randomized trials of male circumcision
[102,103,104], suggest also a substantial role for the lack of male
circumcision in explaining the differences in HIV prevalence.
The evidence to date does not determine whether there is a
biological interaction between HSV-2 and male circumcision. Since
circumcision protection is constrained to the forehead of the penis
while HSV-2 reactivation in the sacral ganglia affects a much larger
surface area of the male genitalia [102,105], the interaction between
the two biological cofactors may be limited. A recent meta-analysis
suggests no significant circumcision protection against HSV-2,
despite protection against other ulcerative STIs [105]. Two of the
male circumcision trials found no efficacy for male circumcision in
Figure 4. HSV-2 role in different risk groups. Role of HSV-2 in fueling HIV spread per sexual activity group in the calculations of
Figure 1 (A and C) and Figure 2 (B and D). The upper panels A and B show the time course of HIV incidence per year attributed directly to HSV-2
in the low-risk population and in the high risk group. The lower panels C and D display the cumulative incidence of HIV infections since 1980 (actual
number of infections) attributed directly to HSV-2 in the low-risk population and in the high risk group.
doi:10.1371/journal.pone.0002230.g004
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private communication. Nevertheless, a reduction of GUD has been
observed in two of the circumcision trials [103,104,106] suggesting
the possibility of a protective effect against symptomatic HSV-2
reactivations. Noteworthy isthatwhile circumcisionoffersprotection
for men, most of the HSV-2 impact on HIV is among women who
are generally twice as likely to be HSV-2 seropositive [11].
We found that the excess prevalence of HSV-2 due to HIV is
much smaller than that of HIV due to HSV-2 (Figures 1C and
2C). The impact of HIV on HSV-2 is mediated by the increased
HSV-2 shedding in dually infected patients which is counterbal-
anced by AIDS mortality as HSV-2 positive persons are more
likely to acquire HIV and die from AIDS. The impact of increased
shedding is generally larger than that of AIDS mortality. The
stability of HSV-2 prevalence throughout the HIV epidemic has
been also seen in earlier modeling work on the role of STIs
[5,6,107], and is consistent with the similar HSV-2 prevalence
levels in Rakai and Mwanza despite the disparity in the severity of
the two HIV epidemics [62]. Furthermore, the similar HSV-2
prevalence levels observed in a cohort in Uganda in the early
1990s [108] and in the Four City study in Kisumu in the late
1990s [11], suggest also that HSV-2 prevalence may have
saturated at about 50% as a population average with little impact
of HIV. The rapid HSV-2 epidemic expansion in Africa, which
appears to have started in the first half of the twentieth century
[109], seems to have reached its peak and saturated prior to the
HIV epidemic in some parts of sub-Saharan Africa.
Sinceatleast75%ofallmucosalulcerationsduetoHSV-2arenot
clinically apparent [73,74,75], the role of GUD due to HSV-2 in our
model accounts for only a minor component, of no more than 25%,
of the total impact of HSV-2 on HIV in contrast to the assessment in
Freeman et al. [100]. The empirical evidence about HSV-2 natural
history and its high frequency of subclinical reactivations is at odds
with assuming such a large PAF due to GUD. In Rakai, the PAF due
to GUD of all etiologies was estimated to be only about 20%
including the effects on both HIV acquisition and transmission [61],
which is consistent with our estimates. The high PAFs in Freeman et
al. model, even for single GUD etiologies such as chancroid, are a
consequence of the assumed large cofactor effects with GUD (for
example a 25-fold increasedper-contacttransmission inthe presence
of chancroid) and the assumed high prevalence of GUD (such as
almost 4% prevalence for chancroid in the early phase of the HIV
epidemic). In our view these assumptions exaggerate the role of
GUD in the HIV dynamics and are not supported by biological
evidence [110].
Our approach for a larger role of HSV-2 subclinical ulcerations
compared to GUD suggests that syndromic or episodicmanagement
of HSV-2 ulcers would have limited impact on reducing HIV
incidence. However if HSV-2 suppressive therapy can effectively
reduce either HIV acquisition or transmission, such therapy offers a
potential tool to influence the HIV epidemic. Our analysis suggests
that an effective therapeutic or prophylactic HSV-2 vaccine could
also reduce HIV acquisition and transmission. The recent results of
HSV-2 syndromic and suppressive therapy trials illustrate these
issues. Syndromic therapywith acyclovir had limited impacton HIV
plasma viral load and HIV genital shedding [111,112], whereas
suppressive therapy resulted in substantial reductions in both plasma
and genital HIV shedding irrespective of the presence of clinical
genital herpes symptoms [46,47,48,49].
Limitations of this model include the possibility of sexual risk
behavior confounding, in the measured relative risk ratios, affecting
our quantitative predictions of the size of the epidemiologic synergy.
The observed high risk of HSV-2 acquisition in HIV seropositive
subjects relative to HIV seronegative persons [108,113], despite the
limited evidence for a compelling biological mechanism apart from
immunosuppression due to HIV, is an indicator of the possibility of
such confounding. There are also several methodological problems
in the derivation and interpretation of HIV and STI biological
cofactors, and measurements of the enhanced acquisition among
susceptible partners can be inflated by exposure to the enhanced
infectivity of their partners if the STI was present in both partners
[114]. However, we minimized these limitations by the conservative
assumptions we employed in our derivations of the per-exposure
cofactors. We derived the PECAcq from the RR assuming that the RR
was measured in partnerships where both partners are HSV-2
seropositive (Protocol S2). We also found that the PECAcq derived
using the RR to be consistent with that derived using the Rakai data
of HIV transmission probabilities (Protocol S2), where the role of
confounding is likely minimal due to the study design of
monogamous partnerships and confirmation of within partnership
transmission [17,37,115]. Our predictions for the PAFSus, and even
for the PAFSus+Inf, are still substantially smaller than those derived in
Figure 5. Epidemiologic synergy between HIV and HSV-2. Measures of the impact on HIV of the epidemiologic synergy between the two
infections in diverse HSV-2 settings. The PAFSus, PAFInf, PAFSus+Inf, and HIV excess prevalence as a function of HSV-2 prevalence. The HIV prevalence in
absence of interaction is at 20%.
doi:10.1371/journal.pone.0002230.g005
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[118].
In conclusion, the prominent effect of HSV-2 in fueling the HIV
epidemic in sub-Saharan Africa is related to 1) the biology of HSV-2
as a chronic infection and a leading cause of clinical and sub-clinical
genital mucosal disruption, 2) the high HSV-2 prevalence, 3)
enhanced HIV acquisition in HSV-2 seropositive persons, and 4)
enhanced HIV infectivity in dually infected subjects. Our model
projects that HSV-2 has played a leading role in fueling HIV spread
in sub-Saharan Africa, and may be responsible for one-third of the
differential HIV prevalenceintheFourCitystudy.Ourcurrent tools
for reducing the impact of HSV-2, such as use of HSV-specific
antivirals like acyclovir to suppress HSV-2 reactivation, may not be
effective enough to reduce the effect of HSV-2 on increasing HIV
susceptibility,whichcontributestotheHSV-HIVsynergy.However,
an HSV-2 vaccine may be an effective intervention to prevent the
interaction of the two infections by removing HSV-2 as a risk factor
for HIV acquisition and transmission. Additionally, ongoing trials
will soon inform us of the potential role of antiviral suppression of
HSV-2 to reduce HIV transmission and disease progression, which
could still have an important impact in interrupting the synergy
between these two viruses.
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